BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Porras D, Nistal E, Martínez-Flórez S, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front Physiol 2018;9:1813. [PMID: 30618824 DOI: 10.3389/fphys.2018.01813] [Cited by in Crossref: 35] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Yuan C, Yang Z, Liu S, Zhang Q, Zhang S, Zhu S. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med 2022;20. [DOI: 10.1186/s12916-022-02460-8] [Reference Citation Analysis]
2 Palade CM, Vulpoi GA, Vulpoi RA, Drug VL, Barboi OB, Ciocoiu M. The Biotics Family: Current Knowledge and Future Perspectives in Metabolic Diseases. Life (Basel) 2022;12:1263. [PMID: 36013442 DOI: 10.3390/life12081263] [Reference Citation Analysis]
3 Cai H, Li D, Song L, Xu X, Han Y, Meng K, Wen Z, Yang P. Metabolomic Characteristics of Liver and Cecum Contents in High-Fat-Diet-Induced Obese Mice Intervened with Lactobacillus plantarum FRT10. Foods 2022;11:2491. [DOI: 10.3390/foods11162491] [Reference Citation Analysis]
4 Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol 2022;28:425-72. [PMID: 35850495 DOI: 10.3350/cmh.2022.0186] [Reference Citation Analysis]
5 Gorelick J, Assa-glazer T, Zandani G, Altberg A, Sela N, Nyska A, Madar Z. THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet. J Cannabis Res 2022;4. [DOI: 10.1186/s42238-022-00137-w] [Reference Citation Analysis]
6 Li L, Ma L, Wen Y, Xie J, Yan L, Ji A, Zeng Y, Tian Y, Sheng J. Crude Polysaccharide Extracted From Moringa oleifera Leaves Prevents Obesity in Association With Modulating Gut Microbiota in High-Fat Diet-Fed Mice. Front Nutr 2022;9:861588. [PMID: 35548566 DOI: 10.3389/fnut.2022.861588] [Reference Citation Analysis]
7 Smirne C, Croce E, Di Benedetto D, Cantaluppi V, Comi C, Sainaghi PP, Minisini R, Grossini E, Pirisi M. Oxidative Stress in Non-Alcoholic Fatty Liver Disease. Livers 2022;2:30-76. [DOI: 10.3390/livers2010003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Juárez-Fernández M, Porras D, Petrov P, Román-Sagüillo S, García-Mediavilla MV, Soluyanova P, Martínez-Flórez S, González-Gallego J, Nistal E, Jover R, Sánchez-Campos S. The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. Antioxidants (Basel) 2021;10:2001. [PMID: 34943104 DOI: 10.3390/antiox10122001] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Zhang J, Li Y, Xiao G, Li Y, Xie H, Chen Y. Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora. Liver Research 2021;5:217-23. [DOI: 10.1016/j.livres.2021.06.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zeybel M, Altay O, Arif M, Li X, Yang H, Fredolini C, Akyildiz M, Saglam B, Gonenli MG, Ural D, Kim W, Schwenk JM, Zhang C, Shoaie S, Nielsen J, Uhlén M, Borén J, Mardinoglu A. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. Mol Syst Biol 2021;17:e10459. [PMID: 34694070 DOI: 10.15252/msb.202110459] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Huang SW, Ou YC, Tang KS, Yu HR, Huang LT, Tain YL, Lin IC, Sheen JM, Hou CY, Tsai CC, Tiao MM. Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis. Lipids Health Dis 2021;20:100. [PMID: 34496884 DOI: 10.1186/s12944-021-01521-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Tang C, Tao J, Sun J, Lv F, Lu Z, Lu Y. Regulatory mechanisms of energy metabolism and inflammation in oleic acid-treated HepG2 cells from Lactobacillus acidophilus NX2-6 extract. J Food Biochem 2021;45:e13925. [PMID: 34486133 DOI: 10.1111/jfbc.13925] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Hu Y, He J, Zheng P, Mao X, Huang Z, Yan H, Luo Y, Yu J, Luo J, Yu B, Chen D. Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 34292103 DOI: 10.1080/10408398.2021.1955654] [Reference Citation Analysis]
14 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
15 Matsui M, Fukunishi S, Nakano T, Ueno T, Higuchi K, Asai A. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. mBio 2021;12:e0115521. [PMID: 34225483 DOI: 10.1128/mBio.01155-21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Mocanu V, Zhang Z, Deehan EC, Kao DH, Hotte N, Karmali S, Birch DW, Samarasinghe KK, Walter J, Madsen KL. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med 2021;27:1272-9. [PMID: 34226737 DOI: 10.1038/s41591-021-01399-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 33] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vasques-Monteiro IML, Silva-Veiga FM, Miranda CS, de Andrade Gonçalves ÉCB, Daleprane JB, Souza-Mello V. A rise in Proteobacteria is an indicator of gut-liver axis-mediated nonalcoholic fatty liver disease in high-fructose-fed adult mice. Nutr Res 2021;91:26-35. [PMID: 34130208 DOI: 10.1016/j.nutres.2021.04.008] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
18 Strasser B, Wolters M, Weyh C, Krüger K, Ticinesi A. The Effects of Lifestyle and Diet on Gut Microbiota Composition, Inflammation and Muscle Performance in Our Aging Society. Nutrients 2021;13:2045. [PMID: 34203776 DOI: 10.3390/nu13062045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hong Y, Sheng L, Zhong J, Tao X, Zhu W, Ma J, Yan J, Zhao A, Zheng X, Wu G, Li B, Han B, Ding K, Zheng N, Jia W, Li H. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. Gut Microbes 2021;13:1-20. [PMID: 34125646 DOI: 10.1080/19490976.2021.1930874] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
20 Milton-Laskibar I, Marcos-Zambrano LJ, Gómez-Zorita S, Fernández-Quintela A, Carrillo de Santa Pau E, Martínez JA, Portillo MP. Gut Microbiota Induced by Pterostilbene and Resveratrol in High-Fat-High-Fructose Fed Rats: Putative Role in Steatohepatitis Onset. Nutrients 2021;13:1738. [PMID: 34065444 DOI: 10.3390/nu13051738] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
21 Pandol S. The Future of Gastrointestinal Physiology: 2020 and Beyond. Front Physiol 2021;12:674951. [PMID: 33912078 DOI: 10.3389/fphys.2021.674951] [Reference Citation Analysis]
22 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
24 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
25 Nallappan D, Chua KH, Ong KC, Chong CW, Teh CSJ, Palanisamy UD, Kuppusamy UR. Amelioration of high-fat diet-induced obesity and its associated complications by a myricetin derivative-rich fraction from Syzygium malaccense in C57BL/6J mice. Food Funct 2021;12:5876-91. [PMID: 34019055 DOI: 10.1039/d1fo00539a] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Juárez-Fernández M, Porras D, García-Mediavilla MV, Román-Sagüillo S, González-Gallego J, Nistal E, Sánchez-Campos S. Aging, Gut Microbiota and Metabolic Diseases: Management through Physical Exercise and Nutritional Interventions. Nutrients 2020;13:E16. [PMID: 33374578 DOI: 10.3390/nu13010016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
27 Singh S, Bhatia R, Khare P, Sharma S, Rajarammohan S, Bishnoi M, Bhadada SK, Sharma SS, Kaur J, Kondepudi KK. Anti-inflammatory Bifidobacterium strains prevent dextran sodium sulfate induced colitis and associated gut microbial dysbiosis in mice. Sci Rep 2020;10:18597. [PMID: 33122795 DOI: 10.1038/s41598-020-75702-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
28 Barchetta I, Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients 2020;12:E3302. [PMID: 33126575 DOI: 10.3390/nu12113302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
29 Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, Du Q, Liao QS, Xie R, Xu JY. Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol 2020; 26(40): 6141-6162 [PMID: 33177790 DOI: 10.3748/wjg.v26.i40.6141] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
30 Lian C, Zhai Z, Li Z, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chemico-Biological Interactions 2020;330:109199. [DOI: 10.1016/j.cbi.2020.109199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
31 Myronovych A, Bhattacharjee J, Salazar-Gonzalez RM, Tan B, Mowery S, Ferguson D, Ryan KK, Zhang W, Zhao X, Oehrle M, Setchell KD, Seeley RJ, Sandoval DA, Kohli R. Assessment of the role of FGF15 in mediating the metabolic outcomes of murine Vertical Sleeve Gastrectomy (VSG). Am J Physiol Gastrointest Liver Physiol 2020. [PMID: 32967428 DOI: 10.1152/ajpgi.00175.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kaufmann B, Reca A, Wang B, Friess H, Feldstein AE, Hartmann D. Mechanisms of nonalcoholic fatty liver disease and implications for surgery. Langenbecks Arch Surg 2021;406:1-17. [PMID: 32833053 DOI: 10.1007/s00423-020-01965-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Knudsen C, Neyrinck AM, Lanthier N, Delzenne NM. Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? Curr Opin Clin Nutr Metab Care 2019;22:393-400. [PMID: 31219825 DOI: 10.1097/MCO.0000000000000584] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
34 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
35 Chiou YL, Chyau CC, Li TJ, Kuo CF, Kang YY, Chen CC, Ko WS. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Coll Nutr 2021;40:349-57. [PMID: 32657670 DOI: 10.1080/07315724.2020.1779850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Diez-Echave P, Vezza T, Rodríguez-Nogales A, Hidalgo-Garcia L, Garrido-Mesa J, Ruiz-Malagon A, Molina-Tijeras JA, Romero M, Robles-Vera I, Leyva-Jiménez FJ, Lozano-Sanchez J, Arráez-Román D, Segura-Carretero A, Micol V, García F, Morón R, Duarte J, Rodríguez-Cabezas ME, Gálvez J. The Beneficial Effects of Lippia Citriodora Extract on Diet-Induced Obesity in Mice Are Associated with Modulation in the Gut Microbiota Composition. Mol Nutr Food Res 2020;64:e2000005. [PMID: 32415899 DOI: 10.1002/mnfr.202000005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
37 Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr 2021;40:207-16. [PMID: 32536582 DOI: 10.1016/j.clnu.2020.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
38 Xu Y, Guo W, Zhang C, Chen F, Tan HY, Li S, Wang N, Feng Y. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application. Front Pharmacol 2020;11:601. [PMID: 32477116 DOI: 10.3389/fphar.2020.00601] [Cited by in Crossref: 12] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
39 Li T, Chiang JYL. Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease. Hepatobiliary Surg Nutr 2020;9:152-69. [PMID: 32355674 DOI: 10.21037/hbsn.2019.09.03] [Cited by in Crossref: 17] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
40 Zhang X, Zhang N, Kan J, Sun R, Tang S, Wang Z, Chen M, Liu J, Jin C. Anti-inflammatory activity of alkali-soluble polysaccharides from Arctium lappa L. and its effect on gut microbiota of mice with inflammation. Int J Biol Macromol 2020;154:773-87. [PMID: 32199919 DOI: 10.1016/j.ijbiomac.2020.03.111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
41 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 49] [Article Influence: 12.5] [Reference Citation Analysis]
42 Bao N, Chen F, Dai D. The Regulation of Host Intestinal Microbiota by Polyphenols in the Development and Prevention of Chronic Kidney Disease. Front Immunol 2019;10:2981. [PMID: 31969882 DOI: 10.3389/fimmu.2019.02981] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
43 Gómez-Zorita S, Aguirre L, Milton-Laskibar I, Fernández-Quintela A, Trepiana J, Kajarabille N, Mosqueda-Solís A, González M, Portillo MP. Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models. Nutrients 2019;11:E2156. [PMID: 31505802 DOI: 10.3390/nu11092156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
44 Fontes A, Alemany-Pagès M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Int J Mol Sci 2019;20:E3987. [PMID: 31426291 DOI: 10.3390/ijms20163987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
45 Petrov PD, García-Mediavilla MV, Guzmán C, Porras D, Nistal E, Martínez-Flórez S, Castell JV, González-Gallego J, Sánchez-Campos S, Jover R. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900487. [PMID: 31322321 DOI: 10.1002/mnfr.201900487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
46 Carbajo-Pescador S, Porras D, García-Mediavilla MV, Martínez-Flórez S, Juarez-Fernández M, Cuevas MJ, Mauriz JL, González-Gallego J, Nistal E, Sánchez-Campos S. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech 2019;12:dmm039206. [PMID: 30971408 DOI: 10.1242/dmm.039206] [Cited by in Crossref: 34] [Cited by in F6Publishing: 53] [Article Influence: 11.3] [Reference Citation Analysis]
47 Porras D, Nistal E, Martínez-Flórez S, Olcoz JL, Jover R, Jorquera F, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice. Mol Nutr Food Res 2019;63:e1800930. [PMID: 30680920 DOI: 10.1002/mnfr.201800930] [Cited by in Crossref: 28] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]